Anti-Human CEACAM‑8/CD66b Reference Antibody (Besilesomab, RUO)

Description: Besilesomab (BS10146) is a research-grade recombinant antibody targeting CD67. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Mouse
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD67antigen,CarcinoembryonicantigenCGM6,Carcinoembryonicantigen-relatedcelladhesionmolecule8,CGM6,CD66b,Non-specificcross-reactingantigenNCA-95,CEACAM8
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: BW250/183,CAS:537694-98-7
Background: Cell adhesion molecule CEACAM8 (CD66b) is a ~38 kDa protein. Cell surface glycoprotein that plays a role in cell adhesion in a calcium-independent manner. Mediates heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Heterophilic interaction with CEACAM8 occurs in activated neutrophils.
References:
1. Kuroki, M. et al. (2001) Journal of leukocyte biology 70, 543-50. PMID: 1159019
2. Oikawa, S. et al. (1991) The Journal of biological chemistry 266, 7995-8001. PMID: 2022629
3. Yamanaka, T. et al. (1996) Protein expression and purification 7, 438-46. PMID: 8776764
Note: For research use only. Not suitable for clinical or therapeutic use.